Abstract
Elevated serum uric acid (UA) concentration is considered to be as one of the factors contributing to endothelial dysfunction. However, it does not lead to clinical manifestations, so it is called asymptomatic hyperuricemia (ASH). The purpose of research was to study the effect of ASH on arterial hypertension (AH) followed by its correction.The investigation was held from 2018 to 2019. The prevalence and degree of severity of ASH were studied in 1018 patients with AH. Hyperuricemia was discovered in 78 patients, which was 7.7% of the total number of studied patients. Methods. A retrospective analysis of patients with AH undergoing inpatient treatment was performed. The control group of patients received standard hypotensive therapy. Although, the main group received standard therapy combined with urate-reducing therapy. Results. Comparative analysis showed that hypotensive therapy was effective in both investigated groups. By the way, index of the main group experienced better results, i.e., the systolic blood pressure (SBP) decreased by 18 Hg (11.6%) compared to the control group. In terms of diastolic blood pressure (DBP), it is dropped by 11.8 Hg (12,1%). The positive effect of urate-reducing therapy is the reason for rising efficiency of the therapy at all. Moreover, significant decrease of UA level was experienced from both researched groups. It averaged 38,3 mmol/l, which is 39.2% of the original result. Conclusion. Thus, the adverse effect of ASH on BP in patients with AH can be compensated by prescription of additional urate-reducing therapy to hypotensive drugs, which helps to reduce the adverse effect of ASH. The obtained data should be taken into account when physicians implement a disease management program.